Trial | NCT01930604  Report issue

Title

Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis, a Randomized, Double Blind, Placebo Controlled Study

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    588
Hyperhidrosis is defined as excessive sweating and affects about 2.8 % of the population.

It has been shown to have a deleterious effect on the quality of life measured using the Dermatology Life Quality Index (DLQI) which is one of the most widely used dermatology-specific quality of life instruments. This is comparable to the effect on quality of life in patients with severe psoriasis of the skin as well as to nodulocystic acne patients before treatment with oral isotretinoin.

The clinical effect of Botulinum Toxin (Btx) A has been established in three randomized controlled trials (RCT) in axillary hyperhidrosis. One RCT has indicated a positive effect in palmar hyperhidrosis. Although there is increasing evidence that Btx A and B have a similar effect on hyperhidrosis of other parts of the body (ie hyperhidrosis of the face, trunk, groin and feet) which is reported in case-reports and open studies there is still a great need for more controlled studies. This is why we will carry out this randomized, double-blind, placebo-controlled study to investigate the clinical effect and safety of Btx A in palmar, plantar and inguinal (groins/buttocks) hyperhidrosis and the clinical effect and safety of Btx B in craniofacial and truncal hyperhidrosis, respectively. Besides using the DLQI instrument we will also study Btx A/B to elucidate the impact of this treatment on quality of life using a generic instrument, the effect on anxiety and depressive symptoms, sweating, and patients´global assessment of therapy.
Study Started
Sep 30
2013
Primary Completion
Oct 31
2019
Anticipated
Study Completion
Oct 31
2019
Anticipated
Last Update
Mar 05
2018

Drug NeuroBloc/Myobloc (rimabotulinumtoxinB)

Drug NaCl (placebo)

Drug Botox (onabotulinumtoxinA)

Palmar hyperhidrosis, Botox (onabotulinumtoxinA) Active Comparator

Solution for injection, individual dosing, maximum dose 400 units, single treatment session.

Palmar hyperhidrosis, NaCl Placebo Comparator

Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.

Plantar hyperhidrosis, Botox (onabotulinumtoxinA) Active Comparator

Solution for injection, individual dosing, maximum dose 400 units, single treatment session.

Plantar hyperhidrosis, NaCl Placebo Comparator

Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.

Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...) Active Comparator

Solution for injection, individual dosing, maximum dose 400 units, single treatment session.

Inguinal (groins/buttocks) hyperhidrosis, NaCl Placebo Comparator

Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.

Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...) Active Comparator

Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.

Craniofacial hyperhidrosis, NaCl Placebo Comparator

Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.

Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB) Active Comparator

Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.

Truncal hyperhidrosis, NaCl Placebo Comparator

Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.

Criteria 

Inclusion Criteria:

Informed consent received from patient
Informed consent received from patient´s parents (when patient < 18 years)
Hyperhidrosis of the head, trunk, groins/buttocks, hands or feet
Age > 16 years
Patients must be previously untreated with Btx A/B

If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e. a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom*) throughout the study. If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the study duration of the study, for both female and male, acceptable birth control must be used for at least 3 months after the last dose of study medication.

* A condom alone is not considered an acceptable method for birth control. Two barrier methods only are not considered an acceptable method of birth control.

Patients must have DLQI-score ≥ 10 and HDSS-score ≥ 3

Exclusion Criteria:

Contraindication to Btx
Use of aminoglycosides, tetracyclines , spectinomycin, lincomycin, polymyxin or muscle relaxants
Pregnancy or lactation
Patients unwilling to meet the requirements of the protocol
Other medical or social reasons for exclusion at the discretion of the Investigator
No Results Posted